On this page

Adbry

tralokinumab-ldrm

351(a) Standalone BLA

Overview

Source: Purple Book
Proprietary name
Adbry
Proper name
tralokinumab-ldrm
Licence type
351(a)
BLA number
761180
Applicant
LEO Pharma A/S
Center
CDER
Presentations
2
First licensure
—

Presentations

Source: Purple Book
Every strength and presentation recorded in the Purple Book for this product.
Strength Dosage form Route Presentation Status Licensed
150MG/ML Injection Subcutaneous Pre-Filled Syringe Rx December 27, 2021
300MG/2ML Injection Subcutaneous Autoinjector Rx June 12, 2024

Sources for this page

Purple Book FDA Licence type, presentations, reference product, exclusivity